Abstract 453P
Background
In terms of the clinical outcome and bad prognosis of cancer, the elevation in IL-6 levels is correlated with disease progression. It is believed that the post-vaccination effect increases the levels of IL-6 antagonists, which can slow the growth of cancer cells.
Methods
This research was conducted out on all cancer patients at Dr. Moewardi General Hospital using an observational analytical research design with a cross-sectional study, with a total sample of 120 patients who were divided into groups that had and had not received vaccination. IL-6 levels were measured using blood samples. To identify the correlation between IL-6 levels and COVID-19 vaccination status, we did descriptive analysis and the Chi-square test to examine the data results.
Results
There were 120 respondents in total, which all were processed for the analysis. out of 99 respondents who had full vaccination records. Then, 21 respondents who did not complete their vaccination status or receive the vaccine. Breast cancer is the most common cancer type in this population, which consists of 80 women and 40 males. Then, 59 respondents had increased Il-6 levels, whereas 61 respondents had normal levels. Findings of the research showed no statistically significant relationship between IL-6 levels and vaccination status (p>0.05).
Conclusions
IL-6 levels were used to analyze the relationship between vaccination status and cancer progression, and it was shown that participants who had received immunizations had no more impact on IL-6 levels than those who had not.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Rico Alfredo Hutabarat.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
419P - Breast arterial calcifications on mammogram and its clinical implications
Presenter: Pradeep Kumar Kistampally
Session: Poster viewing 06
420P - Predictive factors of post-operative acute kidney injury after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis: A retrospective cohort study
Presenter: Chito Cabiling
Session: Poster viewing 06
421P - The association between early changes in neutrophil-lymphocyte ratio and survival in patients treated with immunotherapy
Presenter: Deniz Can Guven
Session: Poster viewing 06
422P - Molecular mechanism in prostate cancer with TP53 mutation
Presenter: Bin Hu
Session: Poster viewing 06
423P - Maintaining a national essential medicine list for cancer in Malaysia: Where do we stand?
Presenter: David Lee
Session: Poster viewing 06
424P - The Storm: Paraneoplastic leucomoid reaction - A bad prognostic factor
Presenter: Abdullah Al Mamun Khan
Session: Poster viewing 06
425P - Preliminary study: Assessment of public trust in traditional medicine and medical treatment in cancer patients in Indonesia - Study validity and reliability of the Universitas Sebelas Maret Trust and readiness assessment for cancer patients (UNS – TRAfCP35) questionnaire
Presenter: Widyanti Soewoto
Session: Poster viewing 06
426P - Safety of Sputnik V COVID-19 vaccine in cancer patients receiving chemotherapy: An observational study
Presenter: Alexey Rumyantsev
Session: Poster viewing 06
427P - Oncology combination therapies in Asia-Pacific markets: What are the current access challenges?
Presenter: Gayathri Kumar
Session: Poster viewing 06
428P - Clinical characteristics, laboratory parameters, and hospital outcomes of COVID-19 among patients with and without cancer: A retrospective cohort study
Presenter: PRASHANT SIROHIYA
Session: Poster viewing 06